Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

TPE/1789 stock hub

TPE/1789 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TPE/1789is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

15.7B

Taiwan Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

TPE/1789

In the news

Latest news · TPE/1789

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12P50 15.5P75 22.5

Trailing P/E148.9

P25 14.4P50 18P75 31.9

ROE1

P25 -16.2P50 0.3P75 9.8

ROIC1.1

P25 -11.7P50 -0.2P75 8.8

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TPE/1789 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

237

Groups with data

Currency

TWD

Showing 237 of 237 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Taiwan
Country code	TW
Employees	540
Enterprise value	TWD 13.3B
Exchange	Taiwan Stock Exchange
Financial currency	TWD
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	TW0001789006
Last refreshed	2026-05-10
Market cap	TWD 15.7B
Price	TWD 19.8
Price currency	TWD
Rev Per Employee	5,808,824.07x
Sector	Healthcare
Sic	2834
Symbol	tpe/1789
Website	https://www.scinopharm.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	0.69%
EV Earnings	123.34x
EV/EBIT	141.59x
EV/EBITDA	21.74x
EV/FCF	38.03x
EV/Sales	4.23x
FCF yield	2.23%
P/B ratio	1.52x
P/E ratio	148.92x
P/S ratio	4.99x
PE Ratio10 Y	71.28x
PE Ratio3 Y	77.86x
PE Ratio5 Y	76.76x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	2.98%
EBITDA Margin	18.92%
FCF margin	11.11%
Gross margin	34.75%
Gross Profit	TWD 1.1B
Gross Profit Growth	-7.23%
Gross Profit Growth Q	-2.83%
Gross Profit Growth3 Y	-3.08%
Gross Profit Growth5 Y	-5.39%
Net Income	TWD 107.5M
Net Income Growth	-56.2%
Net Income Growth Q	-64.09%
Net Income Growth Years	0%
Net Income Growth3 Y	-30.35%
Net Income Growth5 Y	-20.43%
Pretax Margin	3.48%
Profit Margin	3.43%
Profit Per Employee	TWD 198,994
Profitable Years	19
ROA	0.49
Roa5y	1.52
ROCE	0.85
ROE	1.02
Roe5y	2.6
ROIC	1.15
Roic5y	3.37

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-5.2%
Cagr15y	-3.74%
Cagr1y	5.26%
Cagr3y	-9.78%
Cagr5y	-4.52%
Div CAGR10	1.95%
Div CAGR3	-0.93%
Div CAGR5	-6.89%
EPS Growth	-57.14
EPS Growth Q	-64.09
EPS Growth Years	0
EPS Growth3 Y	-30.73
EPS Growth5 Y	-20.78
FCF Growth	40.25%
FCF Growth Q	60.6%
FCF Growth3 Y	-16.6%
FCF Growth5 Y	-9.28%
OCF Growth	13.93%
OCF Growth Q	12.98%
OCF Growth10 Y	-8.27%
OCF Growth3 Y	-9.52%
OCF Growth5 Y	-5%
Revenue Growth	-2.26x
Revenue Growth Q	-3.88x
Revenue Growth Years	0x
Revenue Growth3 Y	-0.4x
Revenue Growth5 Y	-0.28x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	TWD 0.26
Assets	TWD 11.9B
Cash	TWD 3.3B
Current Assets	TWD 5.7B
Current Liabilities	TWD 873.5M
Debt	TWD 862.1M
Debt EBITDA	TWD 1.41
Debt Equity	TWD 0.08
Debt FCF	TWD 2.47
Equity	TWD 10.3B
Interest Coverage	8.74
Liabilities	TWD 1.5B
Long Term Assets	TWD 6.1B
Long Term Liabilities	TWD 673.8M
Net Cash	TWD 2.4B
Net Cash By Market Cap	TWD 15.35
Net Cash Growth	0.1%
Net Debt EBITDA	TWD -4.05
Net Debt Equity	TWD -0.23
Net Debt FCF	TWD -6.9
Tangible Book Value	TWD 10.3B
Tangible Book Value Per Share	TWD 13.02
WACC	6.42

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.55
Inventory Turnover	1.14
Net Working Capital	TWD 1.8B
Quick ratio	4.34
Working Capital	TWD 4.9B
Working Capital Turnover	TWD 0.65

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	0.29%
Dividend Growth	16.67%
Dividend Growth Years	1%
Dividend per share	TWD 0.29
Dividend Years	15
Dividend Yield	1.46%
Ex Div Date	2025-07-03
Last Dividend	TWD 0.35
Payout Frequency	Annual
Payout Ratio	257.55%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-41.35%
1Y total return	5.25%
200-day SMA	19.49
3Y total return	-26.56%
50-day SMA	21.11
50-day SMA vs 200-day SMA	50over200
5Y total return	-20.64%
All Time High	86.76
All Time High Change	-77.18%
All Time High Date	2013-10-31
All Time Low	16.25
All Time Low Change	21.85%
All Time Low Date	2025-07-10
ATR	0.59
Beta	0.45
Beta1y	0.28
Beta2y	0.52
Ch YTD	18.21
High	20.3
High52	29.1
High52 Date	2026-01-21
High52ch	-31.96%
Low	19.8
Low52	16.25
Low52 Date	2025-07-10
Low52ch	21.85%
Ma50ch	-6.21%
Price vs 200-day SMA	1.58%
RSI	37.86
RSI Monthly	45.76
RSI Weekly	47.22
Sharpe ratio	0.34x
Sortino ratio	0.72
Total Return	1.75%
Tr YTD	18.21
Tr15y	-43.54%
Tr1m	-9.38%
Tr1w	-1.74%
Tr3m	-15.38%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	TWD 93.6M
Operating Income Growth	-55.31
Operating Income Growth Q	-42.58
Operating Income Growth3 Y	-36.52
Operating Income Growth5 Y	-26.67
Operating margin	2.98

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	247,242,242%
Net Borrowing	93,621,000
Shares Insiders	0.01%
Shares Institutions	1.69%
Shares Out	790,739,222
Shares Qo Q	-0.2%
Shares Yo Y	-0.29%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	TWD 348.5M
Average Volume	897,877.65x
Bv Per Share	13.04
CAPEX	TWD -270.3M
Ch10y	-49.01
Ch15y	-53.62
Ch1m	-9.38
Ch1w	-1.74
Ch1y	3.13
Ch3m	-15.38
Ch3y	-29.66
Ch5y	-26.94
Ch6m	16.47
Change	-0.75%
Change From Open	-2.46
Close	19.95
Days Gap	1.75
Depreciation Amortization	499,973,000
Dollar Volume	15,298,786.8
Earnings Date	2026-05-11
EBIT	TWD 93.6M
EBITDA	TWD 593.6M
EPS	TWD 0.13
F Score	4
FCF	TWD 348.5M
FCF EV Yield	2.63x
FCF Per Share	TWD 0.44
Financing CF	-185,584,000
Fiscal Year End	December
Founded	1,997
Graham Number	6.24616
Graham Upside	-68.45
Income Tax	TWD 1.7M
Investing CF	-272,808,000
Is Primary Listing	1
Last Earnings Date	2026-02-26
Last Report Date	2026-03-31
Last Split Date	2017-08-10
Last Split Type	Forward
Lynch Fair Value	TWD 0.66
Lynch Upside	-96.64
Ma150	20.15
Ma150ch	-1.73%
Ma20	20.78
Ma20ch	-4.73%
Net CF	167,717,000
Next Earnings Date	2026-05-11
Open	20.3
P FCF Ratio	44.93
P OCF Ratio	25.3
Payment Date	2025-07-24
Position In Range	0
Ppne	4,201,692,000
Price Date	2026-05-08
Price EBITDA	TWD 26.38
Ptbv Ratio	1.52
Relative Volume	0.84x
Revenue	3,136,765,000x
Tax By Revenue	0.05x
Tax Rate	1.56%
Tr6m	16.47%
Volume	772,666

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

TPE/1789 dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.5%

$0.29 annual per share

Payout ratio

+257.6%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

-6.9%

1 consecutive years of growth

Total shareholder yield

+1.8%

Next ex-dividend date: 2025-07-03

Performance

TPE/1789 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TPE/1789?

Insider, institutional, and short-interest positioning.

Institutional ownership

+1.7%

Share of float held by funds and institutions

Insider ownership

+0.0%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-0.3%

Negative means the company is buying back shares.

Technical

TPE/1789 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

37.9

Neutral momentum band

Price vs 200-day MA

+1.6%

50/200-day relationship not available

Beta (5Y)

0.45

Less volatile than the market

Sharpe ratio

0.34

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TPE/1789

Hub-level FAQ points readers to the deeper analysis pages.

What is the current tpe/1789 stock rating?

tpe/1789 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full tpe/1789 analysis?

The full report lives at /stocks/tpe/1789/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for tpe/1789?

The latest report frames tpe/1789 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the tpe/1789 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.